Experts Forecast Increase in Brain Cancer in the US
Brain tumors are noncancerous or cancerous masses or growths of abnormal cells in the brain. Brain cancer usually originates in the central nervous system, which is made up of the spinal cord and the brain. Over the last 10 years, this serious and often debilitating ailment has been discussed and well documented, despite it not being as common as other types of cancer.
Research has shown that brain cancer is more common in men, with epidemiologists from GlobalData predicting that over one-half of all newly diagnosed cases in the United States being individuals aged 60 and above. They expect this pattern to continue in the near future, with an increase in the number of diagnosed brain cancer incident cases in the United States hitting 31,000 by 2030, from the 27,000 recorded in 2020. The age distribution of cases is expected to remain similar in both the female and male population.
The severity and type of brain tumor is determined by the proliferative potential of abnormal growth as well as the cells from which the tumor originated. The location of a brain tumor as well as its rate of growth determines the effect it has on the functioning of an individual’s nervous system.
While research has found that radiation exposure may be a risk for the onset of brain cancer in some cases, brain cancer does not have any particular risk factor, except a family history and age. The disease is strongly linked to common comorbidities such as heart disease, diabetes and hypertension, which is likely because of the wide prevalence of these ailments in the older population.
Brain cancer has a relatively poor rate of survival, with 60% of cases surviving only a year after being diagnosed with the ailment and 30% surviving beyond the fifth year of diagnosis. Over the past decade, the rate of survival has improved slightly, particularly in cases that were diagnosed while the disease was in its early stages.
However, the growing aging population proposes that the number of individuals diagnosed with brain cancer will continue increasing in the near future. The diagnosis of brain cancer in its early stages is difficult, because of a lack of clear diagnostic tools, which partly explains the current low rate of survival.
There is hope, however. Various studies are being conducted into biomarkers such as BRAF-V600E, NTRK, IDH1/IDH2, which can help detect the illness in its early stages and forecast the prognosis. These biomarkers may also help explain why some populations are more susceptible to brain cancer than others.
As a number of companies grapple with understanding the specific mechanisms responsible for the development of brain tumors, others including CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are engaged in developing new therapies that could revolutionize brain cancer treatment.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Brain tumors are noncancerous or cancerous masses or growths of abnormal cells in the brain. Brain cancer usually originates in the central nervous system, which is made up of the spinal cord and the brain. Over the last 10 years, this serious and often debilitating ailment has been discussed and well documented, despite it not being as common as other types of cancer.
Research has shown that brain cancer is more common in men, with epidemiologists from GlobalData predicting that over one-half of all newly diagnosed cases in the United States being individuals aged 60 and above. They expect this pattern to continue in the near future, with an increase in the number of diagnosed brain cancer incident cases in the United States hitting 31,000 by 2030, from the 27,000 recorded in 2020. The age distribution of cases is expected to remain similar in both the female and male population.
The severity and type of brain tumor is determined by the proliferative potential of abnormal growth as well as the cells from which the tumor originated. The location of a brain tumor as well as its rate of growth determines the effect it has on the functioning of an individual’s nervous system.
While research has found that radiation exposure may be a risk for the onset of brain cancer in some cases, brain cancer does not have any particular risk factor, except a family history and age. The disease is strongly linked to common comorbidities such as heart disease, diabetes and hypertension, which is likely because of the wide prevalence of these ailments in the older population.
Brain cancer has a relatively poor rate of survival, with 60% of cases surviving only a year after being diagnosed with the ailment and 30% surviving beyond the fifth year of diagnosis. Over the past decade, the rate of survival has improved slightly, particularly in cases that were diagnosed while the disease was in its early stages.
However, the growing aging population proposes that the number of individuals diagnosed with brain cancer will continue increasing in the near future. The diagnosis of brain cancer in its early stages is difficult, because of a lack of clear diagnostic tools, which partly explains the current low rate of survival.
There is hope, however. Various studies are being conducted into biomarkers such as BRAF-V600E, NTRK, IDH1/IDH2, which can help detect the illness in its early stages and forecast the prognosis. These biomarkers may also help explain why some populations are more susceptible to brain cancer than others.
As a number of companies grapple with understanding the specific mechanisms responsible for the development of brain tumors, others including CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are engaged in developing new therapies that could revolutionize brain cancer treatment.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
